- Home
- CUE vs BEAT Comparison
CUE vs BEAT Comparison
Compare CUE & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- BEAT
- Stock Information
- Founded
- CUE 2014
- BEAT 2015
- Country
- CUE United States
- BEAT United States
- Employees
- CUE N/A
- BEAT N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CUE Health Care
- BEAT Technology
- Exchange
- CUE Nasdaq
- BEAT Nasdaq
- Market Cap
- CUE 61.1M
- BEAT 63.5M
- IPO Year
- CUE 2018
- BEAT 2021
- Fundamental
- Price
- CUE $0.56
- BEAT $1.64
- Analyst Decision
- CUE Strong Buy
- BEAT
- Analyst Count
- CUE 2
- BEAT 0
- Target Price
- CUE $3.00
- BEAT N/A
- AVG Volume (30 Days)
- CUE 394.8K
- BEAT 87.3K
- Earning Date
- CUE 11-12-2025
- BEAT 11-13-2025
- Dividend Yield
- CUE N/A
- BEAT N/A
- EPS Growth
- CUE N/A
- BEAT N/A
- EPS
- CUE N/A
- BEAT N/A
- Revenue
- CUE $7,100,000.00
- BEAT N/A
- Revenue This Year
- CUE N/A
- BEAT N/A
- Revenue Next Year
- CUE N/A
- BEAT $28.23
- P/E Ratio
- CUE N/A
- BEAT N/A
- Revenue Growth
- CUE N/A
- BEAT N/A
- 52 Week Low
- CUE $0.54
- BEAT $0.91
- 52 Week High
- CUE $1.75
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CUE 28.56
- BEAT 51.71
- Support Level
- CUE $0.57
- BEAT $1.50
- Resistance Level
- CUE $0.62
- BEAT $1.80
- Average True Range (ATR)
- CUE 0.08
- BEAT 0.14
- MACD
- CUE -0.01
- BEAT -0.00
- Stochastic Oscillator
- CUE 0.53
- BEAT 58.45
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.